Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200
Alpharetta
Georgia
30005
United States
Tel: 678-270-3631
Fax: 678-270-4033
Website: http://www.clearsidebio.com/
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and nonclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Stock Symbol: CLSD
Stock Exchange: NASDAQ
179 articles about Clearside Biomedical, Inc.
-
Clearside Biomedical’s TANZANITE Extension Study In Patients With Macular Edema Associated With Retinal Vein Occlusion Presented At The 40th Annual Macula Society Meeting
6/8/2017
-
Clearside Biomedical Announces First Quarter 2017 Financial Results And Provides Corporate Update
5/10/2017
-
Clearside Biomedical To Report First Quarter 2017 Financial Results On May 10, 2017 – Conference Call To Follow
5/3/2017
-
Clearside Biomedical Announces Completion Of Patient Enrollment In Phase I/II Open Label Clinical Trial Of CLS-TA In Diabetic Macular Edema
4/20/2017
-
Clearside Biomedical To Present At The 2016 Ladenburg Thalmann Healthcare Conference
9/21/2016
-
Clearside Biomedical To Present At The 2016 Wedbush PacGrow Healthcare Conference
8/10/2016
-
Clearside Biomedical Announces Pricing Of Initial Public Offering
6/2/2016
-
Clearside Biomedical To Present Data On Suprachoroidal Drug Administration At 2016 Association for Research in Vision & Ophthalmology Meeting
4/28/2016
-
Clearside Biomedical Announces Positive Preliminary Phase 2 Results In Patients With Macular Edema Associated With Retinal Vein Occlusion
4/26/2016
-
Clearside Biomedical Announces Appointment Of Richard J. Croarkin To The Board Of Directors
2/29/2016
-
Clearside Biomedical Announces Positive Topline Data From Phase 2 Clinical Trial For The Treatment Of Macular Edema Associated With Non-Infectious Uveitis
1/5/2016
-
Clearside Biomedical Completes Enrollment In Phase 2 Clinical Trial Of CLS-TA For The Treatment Of Retinal Vein Occlusion Using Suprachoroidal Space (SCS) Drug Administration
12/14/2015
-
Clearside Biomedical Enrolls First Patient In Phase 3 Clinical Trial Of CLS-TA Using Suprachoroidal Drug Administration
12/7/2015
-
Clearside Biomedical Nabs $20 Million Series C Financing
12/3/2015
-
Clearside Biomedical Announces Fifth Patent Issued In The U.S. Related To Proprietary Microneedle Drug Delivery Methods And Devices
11/12/2015
-
Clearside Biomedical Completes Enrollment In Phase 2 Clinical Trial Of CLS-TA Using Suprachoroidal Space (SCS) Drug Administration
10/12/2015
-
Clearside Biomedical Announces 50th Patient Enrolled Using Suprachoroidal Drug Administration
9/24/2015
-
Clearside Biomedical To Present At The 13th Congress Of International Ocular Inflammation Society (IOIS) In San Francisco, CA
9/22/2015
-
Clearside Biomedical To Present At International Symposium On Ocular Pharmacology And Therapeutics (ISOPT) Clinical Meeting
7/9/2015
-
Clearside Biomedical Announces Favorable End-of-Phase 2 Review With The FDA
6/16/2015